Exact Sciences (NASDAQ: EXAS) saw its stock surge 7.69% in after-hours trading on Monday following the release of its third-quarter 2025 financial results that significantly exceeded analyst expectations. The molecular diagnostics company reported strong earnings and revenue growth, while also raising its full-year 2025 guidance.

The company reported adjusted earnings per share of $0.28, dramatically beating the consensus estimate of a $0.07 loss. Revenue for the quarter came in at $851 million, surpassing the analyst forecast of $810.1 million and representing a 20% increase from the same period last year. Exact Sciences' strong performance was driven by robust growth across its key segments, with screening sales reaching $2.5 billion, up 20% year-over-year, and precision oncology sales climbing 9% to $710 million.

In light of the strong results, Exact Sciences raised its full-year 2025 revenue guidance to a range of $3.22 billion to $3.235 billion, up from the previous forecast of $3.13 billion to $3.17 billion. The company also highlighted the launch of Cancerguard, a new multi-cancer early detection test, which could potentially boost future revenue. With these positive developments, Exact Sciences appears well-positioned to continue its growth trajectory and make a significant impact in the early detection and treatment of cancer.